Background: Sodium phosphate enemas (SPEs) are widely used among hospitalized patients despite their potential to worsen renal failure. Aim: We decided to assess the extent to which this side effect is clinically relevant. Design: We conducted a matched case-control, retrospective study in a cohort of hospitalized patients. Methods: Patients treated and untreated with SPEs were matched for age, gender, baseline creatinine, usage of certain medications and several background diagnoses. Three groups of matched patients (whole study cohort, patients with baseline creatinine > 1.5 mg/dl and those with baseline creatinine > 2 mg/dl) were compared with regards to their creatinine and blood electrolyte concentrations during 3 consecutive hospitalization days after SPE application. Results: Four hundred and twelve patients were included in this study of which 206 were treated by single SPEs. Exact matching was done for the whole study cohort, for 108 patients with baseline creatinine > 1.5 mg/dl and for 58 patients with baseline creatinine > 2 mg/dl. During 3 consecutive days after SPEs, the maximal blood concentrations of creatinine, phosphor and potassium did not differ significantly between treated patients and matched controls, in all three patients' groups. Conclusion: Application of SPEs neither seem to worsen mild to moderate renal failure, nor are associated with hyperphosphatemia or hyperkalemia in patients hospitalized in internal medicine departments.
Introduction
The safety profile of medications is a major obstacle in achieving effective, therapeutic results. Therefore, adverse effects of medications should be appreciated and carefully evaluated in the relevant, patient population. The usage of sodium phosphate based enemas (SPEs) for patients hospitalized in internal medicine departments is both common, and deterring. The main drawbacks of SPEs are potential volume depletion associated kidney injury and electrolyte disturbances.
In the literature, there are case reports [1] [2] [3] and case series 4, 5 describing patients that were harmed by SPEs. Additionally, there are a small number of retrospective studies addressing this issue. 6, 7 One study combined a retrospective analysis and a subsequent interventional study; however, it was done in a noncontrolled manner, in an emergency department and with limited access to patients' medical background information. 8 Importantly, there are no existing studies which used controlled matching of SPE treated and non-treated patients in a large cohort. This exact matching, which we have conducted in our study, is of utmost importance for achieving correct statistical analysis, especially in the patient population of internal medicine departments as they are complex, with multiple comorbidities and nephrotoxic comedications leading to potentially large biases. We conducted a retrospective, exactly-matched, controlled study in order to shed light on the potential safety concerns associated with SPEs usage in internal medicine departments.
Materials and methods
We conducted a retrospective study identifying all patients, admitted to Sheba Medical Center, Israel, between January 2007 and January 2016 who received sodium phosphate fleet enemas (each patient received a single SPE, 3 mmol/ml; 15 ml vial) during their hospitalization in one of Sheba's internal medicine departments. Patients included in the study had at least one creatinine measurement during the week prior to the administration of the SPE and at least one creatinine measurement during the week after SPE administration.
Demographics and blood test results were obtained from Sheba Medical Center's Electronic Medical Record system via MedAS (MedAware Ltd, Israel) and included: age, gender, creatinine, phosphor, potassium and calcium measurements from the week before and the week after SPE administration.
Sheba Medical Center's institutional ethics committee approved the study. Written informed consent was not requested from participants as the clinical data used for this study were anonymized and de-identified prior to analysis.
Statistical analysis
Patients exposed and unexposed to SPEs were matched. Matching criteria were gender, age 6 2 years, Diabetes Mellitus (DM) status, Congestive Heart Failure (CHF) status, Arterial Hypertension (HTN) status, usage of Angiotensin Converting Enzyme Inhibitors (ACE-I), usage of Angiotensin Receptor Blockers (ARBs), usage of and Aldosterone Receptor Antagonists (ARA) and in hospital maximal creatinine 3 days prior usage of SPE 6 0.5 mg/dl. After matching, the exposed and unexposed patients were compared using Wilcoxon signed ranks test (continuous variables) and McNemar test (for Categorical variables). A two-tailed P < 0.05 was considered statistically significant. Categorical variables were expressed as numbers and percentages. Distribution of continuous variables was assessed using histogram and Q-Q plot. Continuous variables were described using median and interquartile range (IQR). 
Results
Overall 206 patients were treated with SPEs and had sufficient clinical and laboratory data required for inclusion in this study. After exact matching with 206 patients that were not treated with SPEs, the findings were as follows (described also in Table 1): After matching for age, gender, existence of CHF, HTN, DM and usage of ACE-I, ARBs and ARA, we found that patients with normal renal function tests, patients with increased creatinine over 1.5 mg/dl and those with creatinine > 2.0 mg/dl, did not differ in rate of metabolic adverse effects after treatment with SPEs when compared with patients that were not treated with SPEs.
Creatinine, phosphor and potassium blood concentrations did not differ significantly between baseline and during 3 consecutive days after SPE application. Calcium levels difference did reach statistical significance but with no clinical relevance.
Discussion
Usage of SPEs for bowl cleansing and constipation resolution is acceptable worldwide. The combination of diarrhea-induced volume depletion and the exposure of colonic mucosa to highly concentrated phosphate solution increase the risk of dehydration, acute kidney injury and electrolyte disturbances. Such potentially lifethreatening complications were previously described in case reports and case-series: Fine and Patterson 1 described two cases of severe hyperphosphatemia following SPEs. Fass et al. 2 described a case of a patient who died after two sequential SPEs were administered, causing fatal electrolyte imbalances and acidosis. Szoke et al. 3 also described a fatal result of SPE administration to a 90-yearsold, CHF patient who presented with severe hyperphosphatemia and died from cardiac arrest prior to hemodialysis treatment. Ori et al. 4 described a series of eleven elderly patients who were treated with SPEs. Among this group there was an extremely high mortality rate of 45% among SPE treated patients. The uncontrolled nature of these series denies the ability to draw firm conclusions from these findings. Mendoza et al. 5 published a literature review of 39 relevant papers. They specified risk factors for SPEs toxicity: 63% of patients having adverse effects had either gastrointestinal motility disorders, cardiovascular diseases or renal failure. This series included many patients that were younger than 18 years of age and is therefore, less relevant for our research questions. Schaefer et al. 6 did a retrospective analysis of a large cohort of 70 499 veterans, who all went through bowel cleansing prior to colonoscopy. They compared, in a multivariate model, the safety profile of SPEs with and without concomitant use of Polyethylenglycol (PEG) solutions. They found out that while SPEs and PEG are not different regarding the short-term risk of renal failure, SPEs were associated, more often than PEG administration, with long-term renal failure. This study included patients prior to screening colonoscopy rather than just hospitalized patients. Therefore, it could not fully answer our research questions with full validity. Furthermore, this study was criticized for not taking into account the potential confounding effects of concomitantly used nephrotoxic agents. 9 Alami et al. 7 recruited 100 patients from an acute geriatric ward (mean age 87.1) with deteriorated renal function (defined as GFR <60 ml/min per 1.73 m 2 ), who were treated with SPEs due to fecal impaction. Their study results, although uncontrolled, showed that while there was a tendency for hyperphosphatemia and GFR decline among patients treated with SPEs, no statistically significant damage was found with the application of such enemas. Although this study indeed included both hospitalized and elderly patients, the lack of control group weakens the potential strength of its conclusions. Niv et al. 8 conducted a two phase study in the population of an emergency department. They showed that the rate of complications, mainly mechanical, decreased after holding the use of SPEs as treatment for acute constipation. Firstly, this study was not controlled. Secondly, this study was performed on a patient population with limited information with regards to their medical background and medications. In addition, of the nine fatalities recorded in this study, only one was related to hyperphosphatemia. As shown in our study results, precise patients' matching enables accurate appreciation of SPEs adverse effects in the respective patient groups, divided according to their basic kidney function tests. Aside from age and gender, we also matched our three patients' groups, for parameters that are potentially nephrotoxic: HTN and diabetes, two major contributors of chronic kidney disease. We also matched for chronic heart failure, which is also frequently associated with either acute or chronic cardio-renal syndromes. The most common medications associated with Glomerular Filtration Rate (GFR) interferences, ACE-I, ARBs and ARA were also matched.
The fact that we found SPEs not to have significant influence on renal function tests and electrolyte imbalances has several important implications: it shows that prudent usage of SPEs is safe for patients in the internal medicine department (changes in calcium levels did reach statistical significance but in a range that is clinically irrelevant). This is an important finding since the use of SPEs for constipation alleviation is an important tool and daily practice in the clinical settings of such departments.
Study limitations
Our study has several limitations. It is a retrospective analysis and therefore, clinical decisions were not blinded to the patients' characteristics. We tried to overcome some potential confounders by exact matching but it remains clear that a prospective study would have been more accurate. In addition, most patients included in our study were well hydrated during their hospitalization. It is only reasonable to assume that physician monitored hydration may have contributed to eliminate some of the potential deleterious effects of SPEs found in previous studies.
Conclusions
SPEs are relatively safe with regards to kidney function and serum electrolytes' concentrations in the general population of hospitalized patients in internal medicine departments. Our conclusion includes patients with decreased GFR, however, it should be applied only for hospitalized patients. 
